ALLOX
Also known as Allostery Exploration Technologies
Measures the effects of thousands of protein mutations at once to map allosteric and other regulatory sites, and builds AI models on that data to find drug-binding spots on hard targets such as protein-protein interactions and transcription factors, for its own small molecules.
Money and evidence
No research by this company is on the record yet.
Rounds and research, on one timeline
- 2026-10-29SeedRound
US$10.5M (€9.4M)
For: scale the platform, build proprietary AI models that predict therapeutic hotspots, grow the drug discovery team and advance small-molecule programmes, plus pharma research collaborations
Wet labModels and platformHiring
The company's GlobeNewswire release, read in a syndicated copy. Asabys invested through Sabadell Asabys Health Innovation Investments II and 2B; the release gives the dollar figure first.
Lead · AsabysCDTI (Innvierte)Institut Català de Finances
On the deal: Clara Campàs (Co-Founder and Managing Partner, Asabys Partners; spoke for the lead in the announcement, Asabys)
Announced by the company · manilatimes.net ↗On the timeline →
Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.